Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 2/2018

01-02-2018 | Original Research Paper

Inhibitory effects and related molecular mechanisms of total flavonoids in Mosla chinensis Maxim against H1N1 influenza virus

Authors: Xiao-xia Zhang, Qiao-feng Wu, Yun-liang Yan, Feng-ling Zhang

Published in: Inflammation Research | Issue 2/2018

Login to get access

Abstract

Objective

The Shixiangru (Mosla chinensis Maxim) total flavonoids (STF) mainly contain luteolin and apigenin. The study aims to examine the inhibitory effects of STF on anti-H1N1 influenza virus and its related molecular mechanisms in pneumonia mice.

Methods

The viral pneumonia mice were treated with Ribavirin or various doses of STF. We observed histological changes of lung by immunohistochemistry and measured lung index to value anti-influenza virus effects of STF. The concentrations of inflammatory cytokines and anti-oxidant factors were detected by ELISA. RT-PCR and western blot assays were used to determine the expression level of TLR pathway’s key genes and proteins in lung tissues.

Results

We found that the pathological changes of lung in the viral pneumonia mice obviously alleviated by STF treatments and the STF (288 or 576 mg/kg) could significantly decrease lung indices. Moreover, the up-regulation (IL-6, TNF-α, IFN-γ, and NO) and down-regulation (IL-2, SOD and GSH) of inflammatory cytokines and anti-oxidant factors were associated with higher clearance of virus and reduction of inflammatory lung tissue damage. Meanwhile, the expression levels of TLR3, TLR7, MyD88, TRAF3 and NF-κB p65 of the TLR pathway were reduced by STF treatment.

Conclusions

This study suggested that STF may be a promising candidate for treating H1N1 influenza and subsequent viral pneumonia.
Literature
1.
Boni MF, de Jong MD, van Doorn HR, Holmes EC. Guidelines for identifying homologous recombination events in influenza A virus. PLoS One. 2010;(5):e10434.
2.
Lin JH, Chiu SC, Lin YC, Cheng JC, Wu HS, Salemi M, Liu HF. Exploring the molecular epidemiology and evolutionary dynamics of influenza A virus in Taiwan. PLoS One. 2013;8(4):e61957.PubMedPubMedCentralCrossRef
3.
Seo S, Englund JA, Nguyen JT, Pukrittayakamee S, Lindegardh N, Tarning J, Tambyah PA, Renaud C, Went GT, de Jong MD, Boeckh MJ. Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics. Antivir Ther. 2013;18(3):377–86.PubMedCrossRef
4.
Li YH, Lin ZF, Zhao MQ, Guo M, Xu TT, Wang CB, Xia HM, Zhu B. Reversal of H1N1 influenza virus-induced apoptosis by silver nanoparticles functionalized with amantadine. Rsc Adv. 2016;6(92):89679–86.CrossRef
5.
Karthick V, Ramanathan K. Computational investigation of oseltamivir resistance in influenza A (H5N1) virus. Med Chem Res. 2013;22(12):5764–71.CrossRef
6.
Yu CH, Yu WY, Zhong YS, Dai XY, Wu XN, Wu QF. Phytochemical and ethnopharmacological review on Mosla species. Chin Arch Tradit Chin Med. 2013;8:1700–4.
7.
Ge B, Lu XY, Yi K, Jiang HM. Research overview of Mosla chinensis Maxim. Chin Med Mater. 2004;27(4):302–5.
8.
National Pharmacopoeia Committee. Pharmacopoeia of People’s Republic of China. Part 1. Beijing: China Medical Science and Technology Press; 2015. p. 259–60.
9.
Zhang Q, Hao YY, Yu CH, Wu QF. Optimisation for flavonoids extraction from Mosla chinensis Maxim by response surface method. Chi Arch Trad Chin Med. 2012;30(1):116–8.
10.
Yan YF, Chen X, Yang XQ, Wang D, Dong CY, Wu SH. A preliminary study of the active ingredients of volatile oil from Mosla chinensis Maxin. Acta Acad Med QingDao Univ. 2002;38(2):155–7.
11.
Li M, Miao MS. Characteristic analysis of the Elsholtzia chemistry, pharmacology in clinical application. Chin J Chin Mater Med. 2015;30(4):578–9.
12.
Jiang S, Tang H, Xiao GS. Clinical application study of “Xiangru (Mosla Herb).”. Guid J Tradit Chin Med Pharm. 2015;21(9):95–7.
13.
Jiang HJ, Lin Y, Chang Q, Wang YZ, Huang ZQ, Liu ZH. Analysis of the contents of total and three major flavonoids in different tissues of Mosla chinensis. Bull Bot Res. 2012;33(2):252–6.
14.
Lee IK, Hwang BS, Kim DW, Kim JY, Woo EE, Lee YJ, Choi HJ, Yun BS. Characterization of neuraminidase inhibitors in Korean papaver Rhoeas bee pollen contributing to anti-influenza activities in vitro. Planta Med. 2016;82(6):524–9.PubMedCrossRef
15.
Liu AL, Liu B, Qin HL, Lee SM, Wang YT, Du GH. Anti-influenza virus activities of flavonoids from the medicinal plant Elsholtzia rugulosa. Planta Med. 2008;74(8):847–51.PubMedCrossRef
16.
Barral PM, Sarkar D, Su ZZ, Barberd GN, DeSallef R, Racanielloe VR, Fisher PB. Functions of the cytoplasmic RNA sensors RIG-I and MDA-5: key regulators of innate immunity. Pharmacol Ther. 2009;124(2):219–34.PubMedPubMedCentralCrossRef
17.
Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signaling. Nat Rev Immunol. 2008;8(12):911–22.PubMedCrossRef
18.
Koyama S, Ishii KJ, Coban C, Akira S. Innate immune response to viral infection. Cytokine. 2008;43(3):336–41.PubMedCrossRef
19.
Zeng YM. Experimental study on anti influenza virus effect and immune regulation mechanism of toxic heat injection. Beijing: Beijing Univ Chin Med. 2009;57–8.
20.
Pan Y. Antagonism effects and signal transduction path of Hao Qin Qing Dan decotion on Damp-heat syndrome of pneumonia disease infected by influenza virus. Guangzhou: Southern Med Univ. 2009;37–8.
21.
Liu R. Study on the anti-influenza virus effect and TLR/IFN signal pathway mechanism of volatile oil of ramulus cinnamomi and cinnamaldehyde. Chengdu: Chengdu Univ Tradit Chin Med. 2012;84–5.
22.
Wu QF, Yu CH, Yan YL, Chen J, Zhang CC, Wen XX. Antiviral flavonoids from Mosla scabra. Fitoterapia. 2010;81(5):429–33.PubMedCrossRef
23.
Yu CH, Yan YL, Wu XN, Zhang B, Wang W, Wu QF. Anti-influenza virus effects of the aqueous extract from Mosla Scabra. J Ethnopharmacol. 2010;127(2):280–5.PubMedCrossRef
24.
Wu QF, Wang W, Dai XY, Wang ZY, Shen ZH, Ying HZ, Yu CH. Chemical compositions and anti-influenza activities of essential oils from Mosla dianthera. J Ethnopharmacol. 2012;139(2):668–71.PubMedCrossRef
25.
Zhu WY, Chen WB. Respiratory disease. Beijing: People’s Medical Publishing House; 2003. p. 777–8.
26.
Zhang CH, Zhu D, Liu HG. Research Progress on establishment of experimental animal model of influenza virus infection. J Guangxi Med Univ. 2011;28(5):808–11.
27.
Sun XW, Lv CX, Zhang M, Sun XT, Yu B, Zhang G. Immune protective mechanism of Qingying Jiebiao Heji on influenza. Chin J Exp Tradit Med Form. 2010;16(11):161–4.
28.
Jiang Y, Zhang AQ, Wu CY. Immune mechanism of Shuanghua Baidu decoction on children’s seasonal influenza. J Harbin Med Univ. 2012;46(4):370–5.
29.
Gao RB, Bhatnagar J, Blau DM, Greer P, Rollin DC, Denison AM, Carnes MD, Shieh WJ, Sambhara S, Tumpey TM, Patel M, Liu L, Paddock C, Drew C, Shu YL, Katz JM, Zaki SR. Cytokine and chemokine profiles in lung tissues from fatal cases of 2009 pandemic influenza A (H1N1) role of the host immune response in pathogenesis. Am J Pathol. 2013;183(4):1258–68.PubMedCrossRef
30.
Heltzer ML, Coffin SE, Maurer K, Bagashev A, Zhang Z, Orange JS, Sullivan KE. Immune dysregulation in severe influenza. J Leukoc Biol. 2009;85(6):1036–43.PubMedPubMedCentralCrossRef
31.
Kolsuz M, Erginel S, Alataş O, Alataş F, Metintaş M, Uçgun I, Harmanci E, Colak O. Acute phase reactants and cytokine levels in unilateral community-acquired pneumonia. Respiration. 2003;70(6):615–22.PubMedCrossRef
32.
Yang HX. The effect of extract from radix isatidis on influenza virus FM1 strain in vitro and in vivo. Tianjin: Tianjin Med Univ. 2007;41–2.
33.
Vervelde L, Reemers SS, Haarlem DA, Post J, Claassen E, Rebel JMJ, Jansen CA, Vervelde L. Chicken dendritic cells are susceptible to highly pathogenic avian influenzaviruses which induce strong cytokine responses. Dev Comp Immunol. 2013;39(3):198–206.PubMedCrossRef
34.
Sun WM, Wang HQ. Study methodology of cytokines. Beijing: People’s Health Publishing House; 1999. p. 466–86.
35.
Hwang I, Scott JM, Kakarla T, Duriancik DM, Choi S, Cho C, Lee T, Park H, French AR, Beli E, Gardner E, Kim S. Activation mechanisms of natural killer cells during influenza virus infection. PLoS One. 2012;7(12):e51858.PubMedPubMedCentralCrossRef
36.
Wang CX, Gao GX, Wei SC, Xu HR. The dynamic effect of Yiqi Qingwen Jiedu Heji on the protein expressions of cytokine IFN-γ, TNF-α, IL-10 and IL-6 in the lungs of mice Infected by IV FM1. Chin J Chin Mater Med. 2005;30(7):541–4.
37.
Xu BW. Study on effect and immunological mechanisms of Jiaweixuanfeitoujie decoction on Influenza Viral Pneumonia in mice. Beijing: Beijing Univ Chin Med. 2005;30–1.
38.
Qin S, Mo ZY, Zhao SS, Guan WD, Wang YT, Yang ZF. Inhibitory effect of Baicalin on influenza A virus PR8 strain in vitro. Chin Med Mat. 2012;35(2):280–3.
39.
Zarubaev VV, Anfimov PM, Shtro AA, Garshinina AV, Meleshkina IA, Karpinskaia LA, Kozeletskaia KN, Kiselev OI. Development of novel drugs against influenza virus based on synthetic and natural compounds. Vopr Viruso. 2012;57(6):30–6.
40.
Dai JP, Zhao XF, Zeng J, Wan QY, Yang JC, Li WZ, Chen XX, Wang GF, Li KS. Drug screening for autophagy inhibitors based on the dissociation of beclin1–Bcl2 complex using BiFC technique and mechanism of eugenol on anti-influenza A virus activity. PLoS One. 2013;8(4):e61026.PubMedPubMedCentralCrossRef
41.
Rossella F, Ignacio C, Roberta C, Giuliana CC, Luca P, Leonardo M, Ettore N, Paola C, Anna TP, Lucia N, Roberto DS. Effects of polyphenol compounds on influenza A virus replication and definition of their mechanism of action. Bioorg Med Chem. 2012;20(16):5046–52.CrossRef
42.
Shen YL. Hydroxyl radical damage to DNA and RNA bases, quantum chemistry research and analysis of electron density topology on reaction mechanism of flavonoids cleaning hydroxyl free radical. Tianjin: Nankai Univ. 2009;8–9.
43.
Du CF. Antioxidant activity mechanism studies on medicinal plants flavones. Zhengzhou: Zhengzhou Univ. 2011;4–6.
44.
Lu XX. Research Progress in Antioxidant Mechanism of Flavnonids. Food Res Dev. 2012;33(3):220–4.
45.
Akitaka T, Shigeki N, Masafumi S, Kenji F, Naoki L, Yoshifumi L, Taiga M, Koichi L, Hiroshi K, Katsunori Y, Shigeru K. Toll-Like Receptor 4 Agonistic Antibody Promotes Innate Immunity against Severe Pneumonia Induced by Coinfection with Influenza Virus and Streptococcus pneumoniae. Clin Vaccine Immunol. 2013;20(7):977–85.CrossRef
46.
Gu S, Yin N, Pei JF, Lai LH. Understanding molecular mechanisms of traditional Chinese medicine for the treatment of influenza viruses infection by computational approaches. Mol Biosyst. 2013;9(11):2696–700.PubMedCrossRef
47.
Jin D, Lv FL. Molecular mechanism of TLR3 immune recognition of dsRNA virus. Chin J Virol. 2005;21(2):155–9.
48.
49.
Chang XT, Nian XF, Wang ZH. Progress of research on TLRs-mediated signaling pathway. Prog Physiol Sci. 2011;42(5):340–6.
50.
Yi Z, Lin WW, Stunz LL, Bishop GA. Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions. Cytokine Growth F R. 2014;25(2):147–56.CrossRef
51.
Zuo WQ, Zhang YC, Gong XH, Zhang YM. Effects of vasoactive intestinal peptide on Toll-like receptor(TLR)2 mRNA and TLR4 mRNA expression on acute lung injury induced by Hpopolysach aride in rat. Chin J Pediatr. 2010;48(1):19–23.
52.
Zhang J, Miao J, Hou J, Lu C. The effects of H3N2 swine influenza virus infection on TLRs and RLRs signaling pathways in porcine alveolar macrophages. Virol J. 2015;12(1):61.PubMedPubMedCentralCrossRef
53.
Pattabhi S, Courtney RW, Ran D, Megan LK, Jeffrey P, Shari K, Chad EM, Myra LW, Renee CI, Thomas WG, Kristin MB, Shawn PI, Loo YM, Michael GJ. Targeting innate immunity for antiviral therapy through small molecule agonists of the RLR pathway. J Virol. 2015;90(5):2372.PubMedCrossRef
54.
Seo SU, Kwon HJ, Song JH, Byun YH, Seong BL, Kawai T, Akira S, Kweon MN. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J Virol. 2010;84(24):12713–22.PubMedPubMedCentralCrossRef
Metadata
Title
Inhibitory effects and related molecular mechanisms of total flavonoids in Mosla chinensis Maxim against H1N1 influenza virus
Authors
Xiao-xia Zhang
Qiao-feng Wu
Yun-liang Yan
Feng-ling Zhang
Publication date
01-02-2018
Publisher
Springer International Publishing
Published in
Inflammation Research / Issue 2/2018
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-017-1109-4

Other articles of this Issue 2/2018

Inflammation Research 2/2018 Go to the issue

Original Research Paper

Effect of roxithromycin on mucosal damage, oxidative stress and pro-inflammatory markers in experimental model of colitis

Original Research Paper

Diet-induced obesity leads to pro-inflammatory alterations to the vitreous humour of the eye in a rat model

Original Research Paper

Transforming growth factor-β1 and phosphatases modulate COX-2 protein expression and TAU phosphorylation in cultured immortalized podocytes

Original Research Paper

Proinflammatory switch from Gαs to Gαi signaling by Glucagon-like peptide-1 receptor in murine splenic monocyte following burn injury

Commentary

The gestational power of mast cells in the injured tissue

Original Research Paper

Astragaloside IV attenuates orbital inflammation in Graves’ orbitopathy through suppression of autophagy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits